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Melanocytes are specialized pigmented cells that are found in all healthy skin
tissue. In certain individuals, diseased melanocytes can form malignant tumours,
melanomas, which cause the majority of skin-cancer-related deaths. The
melanoma-associated antigenic peptides are presented on cell surfaces via the
class I major histocompatibility complex (MHC). Among the melanoma-
associated antigens, the melanoma self-antigen A/melanoma antigen recognized
by T cells (Melan-A/MART-1) has attracted attention because of its wide
expression in primary and metastatic melanomas. Here, a preliminary X-ray
crystal structural study of a soluble cognate T-cell receptor (TCR) in complex
with a pMHC presenting the Melan-A peptide (ELAGIGILTV) is reported. The
TCR and pMHC were refolded, purified and mixed together to form complexes,
which were crystallized using the sitting-drop vapour-diffusion method. Single
TCR–pMHC complex crystals were cryocooled and used for data collection.
Diffraction data showed that these crystals belonged to space group P41/P43,
with unit-cell parameters a = b = 120.4, c = 81.6 A˚. A complete data set was
collected to 3.1 A˚ and the structure is currently being analysed.
1. Introduction
Melanocytes are specialized pigmented cells that are widespread in
skin and eye tissue (Gray-Schopfer et al., 2007). The degree of
pigment production manifests as skin ‘phototype’ (skin colour and
ease of tanning) and is the most useful predictor of human skin-
cancer risk in the general population (Maresca et al., 2006). The main
contributors to pigmentation are melanins, which are produced by
melanocytes (Gray-Schopfer et al., 2007). The skin provides photo-
protection and thermoregulation by using melanin. Thus, melano-
cytes play a key role in protecting our skin from the damaging effects
of UV radiation and in preventing skin cancer, which occurs at an
estimated 2–3 million cases across the world each year.
The first identified melanoma antigen recognized by T cells
(MART) presented by class I MHC was MAGE (van der Bruggen et
al., 1991). Molecular characterizations of the antigens Melan-A/
MART-1, gp100 and tyrosinase were subsequently reported (Coulie
et al., 1994; Kawakami, Eliyahu, Delgado, Robbins, Rivoltini et al.,
1994; Kawakami, Eliyahu, Delgado, Robbins, Sakaguchi et al., 1994).
In order to increase the weak immunogenicity of these antigens,
attempts were made to modify them: for example, Melan-A/MART-1
26–35 and gp100 209–217 (Parkhurst et al., 1996; Valmori et al., 1998).
Some modifications generated stronger T-cell responses to both wild-
type and modified peptides, whilst other modifications resulted in an
increased response to modified peptides only. How T-cell receptor
(TCR) molecules recognize these presented antigens remains
unclear. Previous work has focused on the mechanisms of melanoma-
antigen presentation by MHC complexes (Sliz et al., 2001; Hu¨lsmeyer
et al., 2005).
Among the many melanoma-associated antigens, Melan-A/
MART-1 has attracted attention because of its wide expression in
primary and metastatic melanomas. It is recognized by about 90% of
tumour-infiltrating lymphocytes (TILs) originating from HLA-
A*0201 patients (Parmiani, 2001). We therefore isolated a TCR from
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a Melan-A-specific CD8+ T-cell clone that recognizes the ELAGI-
GILTV peptide in complex with HLA-A*0201 and crystallized the
trimolecular complex.
2. Materials and methods
2.1. Protein expression
The cDNAs of the TCR - and -chains fromMelan-ACD8+ T-cell
clone Mel5 were isolated using reverse transcription (V12-2,
TRAJ27 and V30, TRBJ2-2). The TCR chains were amplified by
polymerase chain reaction and cloned into the pGMT7 Escherichia
coli expression system as described previously, with mutations to
cysteine at Cys48 and Cys57 and mutation of alanine to Cys75
(Boulter et al., 2003). The extracellular domain of HLA-A*0201 and
2m were cloned into the pGMT7 system as described previously
(Gao et al., 1997).
The plasmids were transformed into E. coli Rosetta DE3 compe-
tent cells and transformed cells were used to inoculate 1 l TYP media
containing ampicillin (100 mg ml1). 1 mM IPTG (isopropyl -d-
thiogalactopyranoside) was used to induce expression for 5 h before
harvesting the cells by centrifugation. The cell pellets were sonicated
in lysis buffer (10 mM Tris–HCl pH 8.0, 150 mM NaCl, 10 mM
EDTA, 2 mM DTT, 0.5 mM PMSF, 100–400 mg ml1 lysozyme, 10%
glycerol, 20 mg ml1 DNAse I) and centrifuged to remove soluble
debris. The resulting inclusion bodies were washed with Triton buffer
(0.5% Triton X-100, 50 mM Tris–HCl pH 8.0, 100 mM NaCl, 0.1%
sodium azide, 10 mM EDTA, 2 mM DTT) and further washed with
resuspension buffer (50 mM Tris–HCl pH 8.0, 100 mM NaCl, 10 mM
EDTA, 2 mM DTT). The washed TCR inclusion bodies were then
dissolved in guanidine buffer (6M guanidine, 50 mM Tris–HCl pH
8.0, 100 mM NaCl, 10 mM EDTA and 10 mM DTT). MHC and 2m
inclusion bodies were separately dissolved in a solution of 10 mM
Tris–HCl pH 8.0, 8M urea and 10 mM DTT. The purity of the
inclusion bodies was assessed by SDS–PAGE.
2.2. Protein refolding and purification
pMHC and TCR protein refolding was carried out as described
previously (Gao et al., 1997; Boulter et al., 2003). Briefly, 60 mg
guanidine-solubilized - and -chain inclusion bodies were mixed in a
1:1 molar ratio and refolded by rapid dilution into 1 l refolding buffer
(5M urea, 0.4M l-arginine, 100 mM Tris pH 8.1, 3.7 mM cystamine,
6.6 mM -mercaptoethylamine) at 277 K. For pMHC refolding, the
peptide was dissolved in DMSO. HLA-A*0201 heavy chain, 2m and
peptide were mixed in a 1:1:3 molecular ratio with a rapid dilution
into 0.4M l-arginine, 100 mM Tris pH 8.0, 2 mM EDTA, 3.7 mM
cystamine and 6.6 mM -mercaptoethylamine. Solutions were mixed
at 277 K for at least 1 h. Dialysis was conducted against 10 mM Tris–
HCl pH 8.1 until the conductivity of the two refolds was less than
1 mS cm1.
The refolded proteins were filtered (0.2 mm) and purified by ion-
exchange chromatography (POROS 50HQ column, PerSeptive
Biosystems Inc.) and gel-filtration chromatography (Superdex-75HR,
GE Healthcare) into crystallization buffer (10 mM Tris–HCl pH 8.1,
10 mM NaCl). The proteins were then separately concentrated to
approximately 10 mg ml1 using 10 kDa centrifugal concentrators
prior to mixing to form the complex for crystallization.
2.3. Crystallization
Concentrated TCR and pMHCwere mixed in a 1:1 molecular ratio.
Crystal screening was initiated using Hampton Research Crystal
Screens 1, 2 and Cryo 1 with drops consisting of 1 ml protein solution
and 1 ml crystallization buffer using the hanging-drop method. Plates
were incubated at 293 K and were analysed after 24 h, 48 h and one
week. Further crystal screens were automated at the Structural
Biology Laboratory, Daresbury using the Innovadyne Screenmaker
96+8 with Qiagen Nextal crystallization coarse screen solutions.
Needle-shaped crystals were observed in a variety of conditions from
Nextal PEGs Suite and Cryos suite after 5 d incubation at 293 K, but
with poor diffraction of up to 30 A˚ resolution.
Optimized crystallization conditions were obtained using an array
of PEG solutions (10–30% PEG 550 MME and PEG 400 pH 6.5–8.5,
15% glycerol) prepared using a Hamilton Microlab STARLET liquid-
handling robot. Crystals (Fig. 1) were harvested from 23% PEG 550
MME, 0.1M Tris pH 7.4 and 15% glycerol after incubation at 293 K
for three weeks.
2.4. Data collection and processing
Data were collected using the rotation method at SRS Station 14.2,
Daresbury, UK with an ADSCQuantum 4 CCD-detector system. The
wavelength was set to 0.979 A˚. A total of 200 frames were recorded,
each covering 0.5 of rotation. The crystal was maintained at 100 K in
an Oxford Cryostream. Reflection intensities were estimated using
the MOSFLM package (Leslie, 1992) and the data were scaled,
reduced and analysed with SCALA and the CCP4 package (Colla-
borative Computational Project, Number 4, 1994). Crystal data and
relevant statistics are given in Table 1.
3. Results and discussion
The pMHC–TCR complex crystals were analysed by X-ray diffrac-
tion and found to belong to space group P41/P43, as deduced from
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Figure 1
Typical appearance of crystals in the sitting drops.
Table 1
Diffraction data statistics.
Values in parentheses are for the highest resolution shell.
Space group P41/P43
Unit-cell parameters (A˚) a = b = 120.4, c = 81.6
Wavelength (A˚) 0.979
Resolution (A˚) 29–3.1 (3.27–3.1)
Measured/unique reflections 81690/21338 (11943/3090)
Completeness (%) 99.8 (100)
Multiplicity 3.8 (3.9)
I/(I) 7.4 (2.1)
Rmerge (%) 20.0 (66.2)
systematic absences, with unit-cell parameters a = b = 120.4, c= 81.6 A˚
(Table 1). One molecule of the complex can be accommodated per
asymmetric unit, giving a VM value of 3.1 A˚
3 Da1 and a solvent
content of 60.5%. A full data set was collected to 3.1 A˚ resolution. A
total of 81 690 observations were measured, including 21 332 unique
reflections. The completeness was 99.8%, with a multiplicity of 3.8
and an Rsym of 20.0%. The Rsym statistic is relatively high, but the
resolution cutoff was determined by an I/(I) value of 2.1 in the
outermost shell, which is acceptable for most applications, particu-
larly with the reasonably high multiplicity of 3.9 in that shell.
Considering that the present work is the result of two rounds of
optimization and screening of a number of crystals, it may be
considered an achievement to obtain this quality of data.
Structure determination and refinement is currently under way.
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